Development of an Actionable Framework to Address Cancer Care Disparities in Medically Underserved Populations in the United States: Expert Roundtable Recommendations We conducted a retrospective ...

July 11, 2007 — The use of intravenous bisphosphonates in cancer patients carries an increased risk for inflammatory conditions or osteomyelitis of the jaw, which may reflect an increase in the risk ...

May 19, 2005 -- The U.S. Food and Drug Administration (FDA) and Novartis Pharmaceuticals Corp. have notified dental healthcare professionals by letter of recommendations that cancer patients ...

There is conflicting evidence regarding bisphosphonates and atrial fibrillation (AF) risk in osteoporosis patients. However, bisphosphonates are used in much higher doses in treatment of bone ...

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

No significant difference in SRE risk on the basis of intravenous bisphosphonate dosing was observed for patients with newly diagnosed multiple myeloma. Credit: Getty Images. Fewer administrations of ...

Abbreviations: SEER, Surveillance, Epidemiology, and End Results; MI, myocardial infarction. We matched 82.7% of nonusers with users on type of cancer, age, sex, SEER region, and bone metastasis. The ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

In patients with cancer and hypercalcemia of malignancy that persists despite treatment with intravenous bisphosphonates, denosumab appears to represent a valid treatment option, according to recent ...

Patients treated with intravenous bisphosphonates are at an increased risk of jaw or facial bone deterioration or infection, according to a study published online June 26 in the Journal of the ...

(HealthDay News) — The risk of atrial fibrillation is increased with use of oral or intravenous bisphosphonates, with a greater risk seen for intravenous vs. oral preparations, according to a review ...